Physician profile
John S Scott
NPI 1154308500
$1,008.59
in general payments reported to CMS, 2019-2025
12 companies · $20.58 in 2025
The $20.58 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2021: $292 · 2022: $257 · 2023: $128 · 2025: $20.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $193.84 | 2019 | |
| Avanos Medical | $128.01 | 2022 | |
| Grifols USA, LLC | $117.30 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.60 | 2022-2023 | Relistor |
| Uswm, LLC | $101.24 | 2021-2023 | Lucemyra, Zimhi |
| Heron Therapeutics, INC. | $89.85 | 2021 | |
| Amgen INC. | $70.03 | 2021 | |
| Scilex Pharmaceuticals INC. | $53.85 | 2022-2023 | Ztlido |
| Boston Scientific Corporation | $51.90 | 2021 | |
| Merck Sharp & Dohme LLC | $35.54 | 2021-2025 | Bridion |
| Collegium Pharmaceutical, INC. | $28.43 | 2021-2022 | |
| Tersera Therapeutics LLC | $26.00 | 2023 | Prialt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.